ArticleJournal of microbiology (Seoul, Korea)2016
The in vitro and in vivo efficacy of fluconazole in combination with farnesol against Candida albicans isolates using a murine vulvovaginitis model.
Article in Journal of microbiology (Seoul, Korea), 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 15 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
15 citing papers in PubMed, 36 citations in OpenAlex.
- The effects of tyrosol on yeasts: an overview of current knowledge.Applied microbiology and biotechnology · 2025Review
- Cyclodextrins in action: ModulatingBiotechnology reports (Amsterdam, Netherlands) · 2025Article
- Antifungal Activity and Type of Interaction ofJournal of fungi (Basel, Switzerland) · 2023Article
- Combination of Farnesol with Common Antifungal Drugs: Inhibitory Effect againstMedicina (Kaunas, Lithuania) · 2023Article
- Farnesol Boosts the Antifungal Effect of Fluconazole and Modulates Resistance inJournal of fungi (Basel, Switzerland) · 2022Article
- Transcriptional Profiling of the Candida auris Response to Exogenous Farnesol Exposure.mSphere · 2021Article
- Fungal Quorum-Sensing Molecules: A Review of Their Antifungal Effect againstJournal of fungi (Basel, Switzerland) · 2020Review
- Optimum Inhibition of Amphotericin-B-ResistantBiomolecules · 2020Article
- Inhibiting roles of farnesol and HOG in morphological switching ofAmerican journal of translational research · 2020Review
- Article
- Article
- Antimicrobial photodynamic therapy as a new approach for the treatment of vulvovaginal candidiasis: preliminary results.Lasers in medical science · 2018Article
- Methodologies forMicrobial cell (Graz, Austria) · 2018Review
- Photodynamic Inactivation Potentiates the Susceptibility of Antifungal Agents against the Planktonic and Biofilm Cells of Candida albicans.International journal of molecular sciences · 2018Article
- The Structure-Activity Relationship of Pterostilbene Against Candida albicans Biofilms.Molecules (Basel, Switzerland) · 2017Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Farnesol is a quorum-sensing molecule that inhibits biofilm formation in Candida albicans. Previous in vitro data suggest that, in combination with certain antifungals, farnesol may have an adjuvant anti-biofilm agent. However, the in vivo efficacy of farnesol is very questionable. Therefore, the in vitro and in vivo activity of fluconazole combined with farnesol was evaluated against C. albicans biofilms using fractional inhibitory concentration index (FICI) determination, time-kill experiments and a murine vulvovaginitis model. The median biofilm MICs of fluconazole-sensitive C. albicans isolates ranged between 4 -> 512 mg/L and 150-300 μM for fluconazole and farnesol, respectively. These values were 512 -> 512 mg/L and > 300 μM for fluconazole-resistant clinical isolates. Farnesol decreased the median MICs of fluconazole by 2-64-fold for biofilms. Based on FICI, synergistic interaction was observed only in the case of the sessile SC5314 reference strain (FICIs: 0.16-0.27). In time-kill studies, only the 512 mg/L fluconazole and 512 mg/L fluconazole + 75 μM farnesol reduced biofilm mass significantly at each time point in the case of all isolates. The combination reduced the metabolic activity of biofilms for all isolates in a concentration- and time-dependent manner. Our findings revealed that farnesol alone was not protective in a murine vulvovaginitis model. Farnesol was not beneficial in combination with fluconazole for fluconazole-susceptible isolates, but partially increased fluconazole activity against one fluconazole-resistant isolate, but not the other one.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.